Active Ingredient(s) | Dosage Form(s) and Strength(s) | Brand(s) | Clinical Indication | Subsidy Class | MediShield Life Claim Limit per month ($) | MediSave Withdrawal Limit per month ($) |
Abemaciclib | Abemaciclib tablet (50 mg, 100 mg, 150 mg) | Verzenio | Abemaciclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer. | MAF | 800 | 600 |
Abemaciclib | Abemaciclib tablet (50 mg, 100 mg, 150 mg) | Verzenio | Abemaciclib in combination with fulvestrant for treating HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy. | MAF | 800 | 600 |
Abiraterone | Abiraterone tablet (250 mg) | - | For cancer treatment. | SDL (Abiranat) | 400 | 600 |
Acalabrutinib | Acalabrutinib capsule (100 mg) | Calquence | Monotherapy for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy. | MAF | 2000 | 600 |
Acalabrutinib | Acalabrutinib capsule (100 mg) | Calquence | Acalabrutinib in combination with obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy. | No subsidy | 2000 | 600 |
Acalabrutinib | Acalabrutinib capsule (100 mg) | Calquence | Monotherapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy. | MAF | 2000 | 600 |
Acalabrutinib | Acalabrutinib capsule (100 mg) | Calquence | Treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy. | MAF | 2000 | 600 |
Afatinib | Afatinib tablet (20 mg, 30 mg, 40 mg) | Giotrif | Treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer. | MAF | 600 | 600 |
Aflibercept | Aflibercept concentrate for solution for infusion (100 mg/4 mL) | Zaltrap | Aflibercept in combination with FOLFIRI for treating metastatic colorectal cancer that has progressed on first-line systemic therapy. | No subsidy | (Undergoing Evaluation) | (Undergoing Evaluation) |
Alectinib | Alectinib capsule (150 mg) | Alecensa | Treatment of locally advanced or metastatic ALK- positive non-small cell lung cancer. | No subsidy | 2000 | 600 |
Anastrozole | Anastrozole tablet (1 mg) | - | Treatment of hormone receptor positive, postmenopausal women with early and advanced breast cancer. | MAF | 200 | 600 |
Apalutamide | Apalutamide tablet (60 mg) | Erleada | Treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). | No subsidy | 400 | 600 |
Apalutamide | Apalutamide tablet (60 mg) | Erleada | Treatment of adult men with metastatic hormone sensitive prostate cancer (mHSPC). | No subsidy | 400 | 600 |
Arsenic trioxide | Arsenic trioxide injection (10 mg) | - | For cancer treatment. | No subsidy | 3000 | 600 |
Atezolizumab | Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) | Tecentriq | Atezolizumab in combination with nab-paclitaxel for treating patients with unresectable, locally advanced, or metastatic triple negative breast cancer whose tumours have PDL1 expression >1% and who have not received prior chemotherapy for metastatic disease. | No subsidy | 1800 | 600 |
Atezolizumab | Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) | Tecentriq | Atezolizumab in combination with a platinum agent and etoposide, for previously untreated extensive-stage small cell lung cancer. | No subsidy | 1800 | 600 |
Atezolizumab | Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) | Tecentriq | For previously untreated metastatic non-small cell lung cancer (NSCLC), in patients whose tumours express PD-L1 with a tumour proportion score ≥50%, with no EGFR or ALK genomic tumour aberrations. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Atezolizumab | Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) | Tecentriq | Treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Atezolizumab | Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) | Tecentriq | Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin, for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who had not received prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Atezolizumab | Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) | Tecentriq | Atezolizumab in combination with nab-paclitaxel and carboplatin, for previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC), in patients with no EGFR or ALK genomic tumour aberrations. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Atezolizumab | Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) | Tecentriq | Treatment of patients with locally advanced or metastatic urothelial carcinoma whose tumours express PD-L1 (PD-L1 stained tumour-infiltrating immune cells [IC] covering ≥5% of the tumour area), and who are not eligible for cisplatin-containing chemotherapy. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Atezolizumab | Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) | Tecentriq | Treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Atezolizumab | Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) | Tecentriq | Treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) after receiving platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for UC. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Atezolizumab | Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) | Tecentriq | Atezolizumab in combination with bevacizumab for treating advanced unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. | No subsidy | 1800 | 600 |
Avelumab | Avelumab concentrate for solution for infusion (200 mg/10 mL) | Bavencio | Treatment of metastatic merkel cell carcinoma. | No subsidy | 1800 | 600 |
Avelumab | Avelumab concentrate for solution for infusion (200 mg/10 mL) | Bavencio | Avelumab in combination with axitinib for untreated advanced renal cell carcinoma. Treatment with PD-1/PD-L1 inhibitor should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Avelumab | Avelumab concentrate for solution for infusion (200 mg/10 mL) | Bavencio | Maintenance treatment of locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-based chemotherapy. | No subsidy | 1800 | 600 |
Axitinib | Axitinib tablet (1 mg, 5 mg) | Inlyta | For previously treated advanced renal cell carcinoma. | No subsidy | 1600 | 600 |
Azacitidine | Azacitidine injection (100 mg) | - | For cancer treatment. | SDL | 400 | 600 |
Bacillus Calmette-Guerin (BCG) | Bacillus Calmette-Guerin (BCG) solution for intravesical use (12.5 mg, 40 mg, 80 mg) | - | For cancer treatment. | SDL | 400 | 600 |
Bendamustine | Bendamustine concentrate for infusion (25 mg and 100 mg) | - | For cancer treatment. | SDL | 800 | 600 |
Bevacizumab | Bevacizumab concentrate for solution for infusion (100 mg/4 mL, 400 mg/16 mL) | (Undergoing Evaluation) | (Undergoing Evaluation) | (Undergoing Evaluation) | (Undergoing Evaluation) | (Undergoing Evaluation) |
Bicalutamide | Bicalutamide tablet (50 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Bleomycin | Bleomycin injection (15 USP unit) | - | For cancer treatment. | SDL | 400 | 600 |
Blinatumomab | Blinatumomab powder for infusion (35 mcg vial) | Blincyto | Treatment of B-cell precursor acute lymphoblastic leukaemia in first or subsequent complete remission with minimal residual disease (MRD) greater than or equal to 0.1% for:
- up to a maximum of one cycle for induction in a lifetime;
- and up to three additional cycles for consolidation in a lifetime in patients who are MRD negative.
Complete remission is defined as a patient who:
a) has 5% or less bone marrow blasts; and
b) has no evidence of disease; and
c) has a full recovery of peripheral blood counts with platelet count of more than 100,000 per microlitre; and
d) absolute neutrophil count of more than 1,000 per microlitre | MAF | 9600 | 1200 |
Blinatumomab | Blinatumomab powder for infusion (35 mcg vial) | Blincyto | Treatment of relapsed or refractory B-precursor acute lymphoblastic leukaemia (r/r B-ALL) for:
- up to a maximum of two cycles for induction in a lifetime; and
- up to three additional cycles for consolidation in a lifetime in patients who achieve a complete response after induction.
Patients with Philadelphia chromosome positive disease must have previously received a tyrosine kinase inhibitor before receiving blinatumomab. Patients must not have received blinatumomab previously for the treatment of minimal residual disease (MRD)-positive B-ALL OR patients must have had a relapse-free period of at least six months following completion of treatment with blinatumomab for MRD. Complete response is defined as a patient who:
- has 5% or less bone marrow blasts; and
- has no evidence of disease; and
- has platelet count of more than 50,000 per microlitre; and
- has absolute neutrophil count of more than 500 per microlitre. | MAF | 9600 | 1200 |
Bortezomib | Bortezomib injection (3.5mg) | (Undergoing Evaluation) | (Undergoing Evaluation) | (Undergoing Evaluation) | (Undergoing Evaluation) | (Undergoing Evaluation) |
Brentuximab vedotin | Brentuximab vedotin powder for infusion (50 mg) | Adcetris | Brentuximab in combination with cyclophosphamide, doxorubicin and prednisone (CHP), for previously untreated CD30+ peripheral T-cell lymphoma. | MAF | 1800 | 600 |
Brentuximab vedotin | Brentuximab vedotin powder for infusion (50 mg) | Adcetris | Treatment of relapsed or refractory systemic anaplastic large cell lymphoma. Treatment should be stopped at 16 cycles, or earlier if disease progresses. | MAF | 1800 | 600 |
Brentuximab vedotin | Brentuximab vedotin powder for infusion (50 mg) | Adcetris | Treatment of patients with CD30+ cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy. Treatment should be stopped at 16 cycles, or earlier if disease progresses. | MAF | 1800 | 600 |
Brentuximab vedotin | Brentuximab vedotin powder for infusion (50 mg) | Adcetris | Treatment of adults with previously untreated CD30+ advanced classic Hodgkin lymphoma (cHL) in combination with doxorubicin, vinblastine and dacarbazine (AVD). | No subsidy | 1800 | 600 |
Brentuximab vedotin | Brentuximab vedotin powder for infusion (50 mg) | Adcetris | Treatment of adults with CD30+ Hodgkin lymphoma (HL) who are at increased risk of relapse or progression following an autologous stem cell transplant (ASCT). Treatment should be stopped at 16 cycles, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Brentuximab vedotin | Brentuximab vedotin powder for infusion (50 mg) | Adcetris | Treatment of adults with relapsed or refractory CD30+ Hodgkin lymphoma (HL):
1. following autologous stem cell transplant (ASCT) or
2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. Treatment should be stopped at 16 cycles, or earlier if disease progresses. | MAF | 1800 | 600 |
Brigatinib | Brigatinib tablet (30 mg, 90 mg, 180 mg) | Alunbrig | Treatment of locally advanced or metastatic ALK- positive non-small cell lung cancer. | MAF | 2000 | 600 |
Busulfan | Busulfan tablet (2 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Cabazitaxel | Cabazitaxel injection (60 mg/1.5 mL) | Jevtana | Cabazitaxel in combination with prednisolone: for the treatment of adult patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen. | No subsidy | 1400 | 600 |
Cabozantinib | Cabozantinib tablet (20 mg, 40 mg, 60 mg) | Cabometyx | For previously treated advanced renal cell carcinoma. | No subsidy | 1800 | 600 |
Cabozantinib | Cabozantinib tablet (20 mg, 40 mg, 60 mg) | Cabometyx | Treatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. | No subsidy | 1800 | 600 |
Cabozantinib | Cabozantinib tablet (20 mg, 40 mg, 60 mg) | Cabometyx | For untreated intermediate- or poor-risk advanced renal cell carcinoma. | No subsidy | 1800 | 600 |
Capecitabine | Capecitabine tablet (150 mg, 500 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Carboplatin | Carboplatin vial (150 mg/15 mL, 450 mg/45 mL) | - | For cancer treatment. | SDL | 200 | 600 |
Carfilzomib | Carfilzomib powder for solution for infusion (30 mg) | Kyprolis | Carfilzomib in combination with lenalidomide or thalidomide or cyclophosphamide, plus dexamethasone, for patients with multiple myeloma who have received at least one prior therapy. Treatment with carfilzomib should be stopped after 18 cycles, or earlier if disease progresses. | MAF | 2000 | 600 |
Carfilzomib | Carfilzomib powder for solution for infusion (30 mg) | Kyprolis | Carfilzomib in combination with dexamethasone for patients with multiple myeloma who have received at least one prior therapy. | MAF | 2000 | 600 |
Carmustine | Carmustine injection (100 mg) | BiCNU | For cancer treatment. | SDL | 2000 | 600 |
Ceritinib | Ceritinib capsule (150 mg) | Zykadia | For cancer treatment. | SDL | 1000 | 600 |
Cetuximab | Cetuximab solution for infusion (100 mg/20 mL) | Erbitux | Cetuximab in combination with platinum-based chemotherapy for patients with unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN). | MAF | 1000 | 600 |
Cetuximab | Cetuximab solution for infusion (100 mg/20 mL) | Erbitux | Cetuximab in combination with radiation therapy for patients with locally advanced squamous cell cancer of the head and neck (LASCCHN) who have contraindications or intolerance to platinum-based chemoradiation therapy. | MAF | 1000 | 600 |
Cetuximab | Cetuximab solution for infusion (100 mg/20 mL) | Erbitux | Cetuximab as monotherapy or in combination with chemotherapy, for treating RAS wild-type metastatic colorectal cancer. | No subsidy | 1000 | 600 |
Chlorambucil | Chlorambucil tablet (2 mg) | Leukeran | For cancer treatment. | SDL | 400 | 600 |
Cisplatin | Cisplatin injection (50 mg/50 mL, 100 mg/100 mL injection) | - | For cancer treatment. | SDL | 200 | 600 |
Crizotinib | Crizotinib capsule (200 mg, 250 mg) | Xalkori | Treatment of patients with locally advanced or metastatic ROS1-positive NSCLC. Patients must not have received prior treatment with other ROS1 inhibitors. | No subsidy | 3000 | 600 |
Cyclophosphamide | Cyclophosphamide vial (1 g) and tablet (50 mg) | Endoxan | For cancer treatment. | SDL | 200 | 600 |
Cyproterone | Cyproterone tablet (50 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Cytarabine | Cytarabine vial (1 g/10 mL) | - | For cancer treatment. | SDL | 400 | 600 |
Dabrafenib plus trametinib | Dabrafenib capsule (50 mg, 75 mg)
Trametinib tablet (0.5 mg, 2 mg) | Tafinlar
Mekinist | Dabrafenib in combination with trametinib for treating locally advanced or metastatic anaplastic thyroid cancer in patients with a BRAF V600 mutation and with no satisfactory locoregional treatment options. | MAF | 3800 | 600 |
Dabrafenib plus trametinib | Dabrafenib capsule (50 mg, 75 mg)
Trametinib tablet (0.5 mg, 2 mg) | Tafinlar
Mekinist | Dabrafenib in combination with trametinib for the adjuvant treatment of completely resected malignant melanoma in patients with BRAF V600 mutation-positive disease and lymph node involvement. Maximum duration of treatment: 12 months. | No subsidy | 3800 | 600 |
Dabrafenib plus trametinib | Dabrafenib capsule (50 mg, 75 mg)
Trametinib tablet (0.5 mg, 2 mg) | Tafinlar
Mekinist | Dabrafenib in combination with trametinib for the treatment of advanced unresectable or metastatic malignant melanoma in patients with a BRAF V600 mutation. Patients must not have received prior treatment with a BRAF/MEK inhibitor for unresectable or metastatic melanoma. | MAF | 3800 | 600 |
Dabrafenib plus trametinib | Dabrafenib capsule (50 mg, 75 mg)
Trametinib tablet (0.5 mg, 2 mg) | Tafinlar
Mekinist | Dabrafenib in combination with trametinib for the treatment of advanced non-small cell lung cancer (NSCLC) in patients with a BRAF V600 mutation. | MAF | 3800 | 600 |
Dacarbazine | Dacarbazine vial (200 mg) | - | For cancer treatment. | SDL | 600 | 600 |
Dacomitinib | Dacomitinib tablet (15 mg, 30 mg, 45 mg) | Vizimpro | For cancer treatment. | SDL | 600 | 600 |
Dactinomycin | Dactinomycin vial (500 mcg) | - | For cancer treatment. | SDL | 1400 | 600 |
Daratumumab | Daratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL) | Darzalex | Daratumumab in combination with bortezomib, thalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant. | No subsidy | 2000 | 600 |
Daratumumab | Daratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL) | Darzalex | Daratumumab in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy. | No subsidy | 2000 | 600 |
Daratumumab | Daratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL) | Darzalex | Daratumumab in combination with bortezomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy. | No subsidy | 2000 | 600 |
Daratumumab | Daratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL) | Darzalex | Daratumumab in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for an autologous stem cell transplant. | No subsidy | 2000 | 600 |
Darolutamide | Darolutamide tablet (300 mg) | Nubeqa | Treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). | No subsidy | 400 | 600 |
Dasatinib | Dasatinib tablet (20 mg, 50 mg, 70 mg) | Sprycel | Treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase. | MAF | 1200 | 600 |
Dasatinib | Dasatinib tablet (20 mg, 50 mg, 70 mg) | Sprycel | Treatment of adults with treatment-resistant or treatment-intolerant chronic myeloid leukemia (CML) in chronic phase, accelerated phase, or myeloid or lymphoid blast phase or children with treatment-resistant or treatment-intolerant CML in chronic phase. | MAF | 1200 | 600 |
Dasatinib | Dasatinib tablet (20 mg, 50 mg, 70 mg) | Sprycel | Treatment of newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia in combination with chemotherapy. | MAF | 1200 | 600 |
Dasatinib | Dasatinib tablet (20 mg, 50 mg, 70 mg) | Sprycel | Treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior treatment with imatinib. | MAF | 1200 | 600 |
Daunorubicin | Daunorubicin vial (20 mg ) | - | For cancer treatment. | SDL | 400 | 600 |
Degarelix | Degarelix injection (80 mg, 120 mg) | Firmagon | Treatment of adults with advanced hormone-dependent prostate cancer. | MAF | 200 | 600 |
Dexamethasone | Dexamethasone injection (4 mg) and tablet (4 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Docetaxel | Docetaxel vial (20 mg , 80 mg, 160 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Doxorubicin | Doxorubicin vial (50 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Durvalumab | Durvalumab concentrate for solution for infusion (120 mg/2.4 mL, 500 mg/10 mL) | Imfinzi | Consolidation treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemo-radiation therapy.
Treatment should be continued until disease progression or unacceptable toxicity or a maximum of 12 months. | MAF | 1800 | 600 |
Durvalumab | Durvalumab concentrate for solution for infusion (120 mg/2.4 mL, 500 mg/10 mL) | Imfinzi | Durvalumab in combination with a platinum agent and etoposide, for previously untreated extensive-stage small cell lung cancer. | MAF | 1800 | 600 |
Entrectinib | Entrectinib capsule (100 mg, 200 mg) | Rozlytrek | Treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. Patients must not have received prior treatment with other ROS1 inhibitors. | No subsidy | 3000 | 600 |
Entrectinib | Entrectinib capsule (100 mg, 200 mg) | Rozlytrek | Treatment of patients with solid tumours that:
- have a NTRK gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory alternative treatments or that have progressed following treatment. | No subsidy | 3000 | 600 |
Enzalutamide | Enzalutamide capsule (40 mg) | Xtandi | Treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). | MAF | 400 | 600 |
Enzalutamide | Enzalutamide capsule (40 mg) | Xtandi | Treatment of adult men with metastatic hormone sensitive prostate cancer (mHSPC). | MAF | 400 | 600 |
Enzalutamide | Enzalutamide capsule (40 mg) | Xtandi | Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC). | MAF | 400 | 600 |
Epirubicin | Epirubicin injection (50 mg/25 mL) | - | For cancer treatment. | SDL | 600 | 600 |
Erdafitinib | Erdafitinib tablet (3 mg, 4 mg, 5 mg) | Balversa | Treatment of patients with locally advanced or metastatic urothelial carcinoma, whose tumours have susceptible FGFR3 genetic alterations, and who have disease progression during or following at least one line of prior chemotherapy including within 12 months of neoadjuvant or adjuvant chemotherapy. | No subsidy | 1800 | 600 |
Eribulin | Eribulin mesylate solution for injection (1 mg/2 mL) | Halaven | Treatment of locally advanced or metastatic breast cancer in patients whose disease has progressed after >= 2 chemotherapy regimens for advanced disease. | MAF | 1200 | 600 |
Eribulin | Eribulin mesylate solution for injection (1 mg/2 mL) | Halaven | Treatment of adults with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease. | MAF | 1200 | 600 |
Erlotinib | Erlotinib tablet (100 mg, 150 mg) | - | For cancer treatment. | SDL (Inerlotinib) | 200 | 600 |
Etoposide | Etoposide capsule (50 mg) | - | For cancer treatment. | SDL | 600 | 600 |
Etoposide | Etoposide vial (100 mg/5 mL) | - | For cancer treatment. | SDL | 200 | 600 |
Everolimus | Everolimus tablet (2.5 mg, 5 mg, 10 mg) | Afinitor | Everolimus in combination with exemestine for HR positive, HER2/neu negative advanced breast cancer, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor. | No subsidy | 1200 | 600 |
Everolimus | Everolimus tablet (2.5 mg, 5 mg, 10 mg) | Afinitor | For previously treated advanced renal cell carcinoma. | No subsidy | 1200 | 600 |
Everolimus | Everolimus tablet (2.5 mg, 5 mg, 10 mg) | Afinitor | Treatment of unresectable, locally advanced or metastatic neuroendocrine tumours of pancreatic origin and with progressive disease. | MAF | 1200 | 600 |
Everolimus | Everolimus tablet (2.5 mg, 5 mg, 10 mg) | Afinitor | Treatment of unresectable or metastatic, well-differentiated, non-functional neuroendocrine tumours of gastrointestinal or lung origin and with progressive disease. | MAF | 1200 | 600 |
Exemestane | Exemestane tablet (25 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Fludarabine | Fludarabine injection (50 mg) | - | For cancer treatment. | SDL | 600 | 600 |
Fluorouracil | Fluorouracil vial (500 mg/10 mL, 1g/20 mL, 5g/100 mL) | - | For cancer treatment. | SDL | 200 | 600 |
Fluorouracil (5-fluorouracil) cream | 5-fluorouracil cream (5%) | - | Treatment of actinic keratosis, Bowen’s disease, or superficial basal cell carcinoma. | No subsidy | 200 | 600 |
Folinic acid | Folinic acid vial (50 mg/5 mL, 300 mg/30 mL) | - | For cancer treatment. | SDL | 200 | 600 |
Fulvestrant | Fulvestrant solution for injection in pre-filled syringe (250 mg/5 mL) | (Undergoing Evaluation) | (Undergoing Evaluation) | (Undergoing Evaluation) | (Undergoing Evaluation) | (Undergoing Evaluation) |
Gefitinib | Gefitinib tablet (250 mg) | - | For cancer treatment. | SDL (Ingefitinib) | 200 | 600 |
Gemcitabine | Gemcitabine vial (200 mg, 1 g, 2 g) | - | For cancer treatment. | SDL | 200 | 600 |
Gilteritinib | Gilteritinib tablet (40 mg) | Xospata | Treatment of FLT-3 mutation positive relapsed / refractory acute myeloid leukaemia (AML).
Gilteritinib is not recommended as maintenance therapy for patients after HSCT. | (Undergoing Evaluation) | (Undergoing Evaluation) | (Undergoing Evaluation) |
Goserelin | Goserelin depot injection (3.6 mg, 10.8 mg) | Zoladex | Treatment of breast cancer in pre- and perimenopausal women in whom hormone therapy is specified. | MAF | 200 | 600 |
Goserelin | Goserelin depot injection (3.6 mg, 10.8 mg) | Zoladex | 1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse.
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer | MAF | 200 | 600 |
Hydroxyurea | Hydroxyurea capsule (500 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Ibrutinib | Ibrutinib capsule (140 mg) and tablet (140 mg, 280 mg, 420 mg)
| Imbruvica | Monotherapy for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are unsuitable for fludarabine-based therapy. | No subsidy | 2000 | 600 |
Ibrutinib | Ibrutinib capsule (140 mg) and tablet (140 mg, 280 mg, 420 mg)
| Imbruvica | Ibrutinib in combination with rituximab biosimilar or obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). | No subsidy | 2000 | 600 |
Ibrutinib | Ibrutinib capsule (140 mg) and tablet (140 mg, 280 mg, 420 mg) | Imbruvica | Monotherapy for patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy. | No subsidy | 2000 | 600 |
Ibrutinib | Ibrutinib capsule (140 mg) and tablet (140 mg, 280 mg, 560 mg) | Imbruvica | Treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy. | No subsidy | 2000 | 600 |
Ibrutinib | Ibrutinib capsule (140 mg) and tablet (140 mg, 280 mg, 420 mg) | Imbruvica | Ibrutinib as a single agent, or in combination with rituximab biosimilar, for the treatment of Waldenstrom’s Macroglobulinaemia. | No subsidy | 2000 | 600 |
Idarubicin | Idarubicin solution for injection (5 mg/5 mL and 10 mg/10 mL) | Zavedos CS | Treatment of acute myeloid leukaemia (AML) in adults for remission induction. | No subsidy | 400 | 600 |
Ifosfamide | Ifosfamide infusion (1 g) | Holoxan | For cancer treatment. | SDL | 2400 | 600 |
Imatinib | Imatinib tablet (100 mg, 400 mg) | - | For cancer treatment. | SDL (Veenat) | 200 | 600 |
Imiquimod cream | Imiquimod cream (5%) | Aldara | Treatment of actinic keratosis or superficial basal cell carcinoma. | No subsidy | 200 | 600 |
Inotuzumab ozogamicin | Inotuzumab ozogamicin powder for concentrate for solution for infusion (1 mg per vial) | Besponsa | Treatment of adults with relapsed or refractory CD22 positive B-cell precursor acute lymphoblastic leukemia (ALL) for:
- up to a maximum of three cycles for induction in a lifetime, and
- up to three additional cycles for consolidation in a lifetime in patients who achieve a complete response after induction
Patients with Philadelphia chromosome positive disease must have previously received a tyrosine kinase inhibitor before receiving inotuzumab.
Complete response is defined as a patient who:
a) has 5% or less bone marrow blasts; and
b) has no evidence of disease; and
c) has platelet count of more than 50,000 per microlitre; and
d) has absolute neutrophil count of more than 500 per microlitre. | MAF | 9600 | 1200 |
Interferon alfa 2a | Interferon alfa 2a injection (3 million iu/ 0.5 mL) | - | For cancer treatment. | SDL | 400 | 600 |
Ipilimumab plus nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)
Ipilimumab injection concentrate (50 mg/10 mL) | Opdivo
Yervoy | For untreated intermediate- or poor-risk advanced renal cell carcinoma. The doses of nivolumab and ipilimumab should not exceed: 3mg/kg nivolumab and 1mg/kg ipilimumab every 3 weeks for 4 doses. Re-induction with ipilimumab is not allowed. | MAF | 5200 | 600 |
Irinotecan hydrochloride trihydrate | Irinotecan hydrochloride trihydrate vial (100 mg/5 mL) | - | For cancer treatment. | SDL | 200 | 600 |
Ixazomib | Ixazomib capsule (3 mg, 4 mg) | Ninlaro | Ixazomib in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy. | MAF | 2000 | 600 |
Lanreotide | Lanreotide prolonged release (PR) injection (60 mg, 90 mg, 120 mg) | Somatuline Autogel | Treatment of neuroendocrine tumours of gastrointestinal or pancreatic origin. | No subsidy | 600 | 600 |
Lanreotide | Lanreotide prolonged release (PR) injection (60 mg, 90 mg, 120 mg) | Somatuline Autogel | For the reduction of symptoms associated with carcinoid syndrome. | No subsidy | 600 | 600 |
Lapatinib | Lapatinib tablet (250 mg) | Tykerb | Lapatinib in combination with an aromatase inhibitor for postmenopausal women with HR positive, HER2 positive metastatic breast cancer. | MAF | 600 | 600 |
Lapatinib | Lapatinib tablet (250 mg) | Tykerb | Lapatinib in combination with capecitabine for HER2 positive, advanced or metastatic breast cancer in patients whose disease has progressed after treatment with an anthracycline and, a taxane, and on prior trastuzumab therapy in the metastatic setting. | MAF | 600 | 600 |
Larotrectinib | Larotrectinib capsule (25 mg, 100 mg) and oral solution (2 g/100 mL) | Vitrakvi | Treatment of patients with solid tumours that:
- have a NTRK gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory alternative treatments or that have progressed following treatment. | No subsidy | 3000 | 600 |
L-asparaginase | L-asparaginase injection (10,000 IU) | Leunase | For cancer treatment. | SDL | 1000 | 600 |
Lenalidomide | Lenalidomide capsule (5 mg, 10 mg, 15 mg, 25 mg) | - | For cancer treatment. | SDL (Lenli) | 1200 | 600 |
Lenvatinib | Lenvatinib capsule (4 mg, 10 mg) | Lenvima | Treatment of advanced unresectable hepatocellular carcinoma in patients with adequate liver function as assessed by the Child-Pugh scoring system, when used according to HSA-recommended dosing regimens. | MAF | 1200 | 600 |
Lenvatinib | Lenvatinib capsule (4 mg, 10 mg) | Lenvima | Treatment of locally advanced or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. | MAF | 1200 | 600 |
Lenvatinib | Lenvatinib capsule (4 mg, 10 mg) | Lenvima | Lenvatinib in combination with everolimus for previously treated advanced renal cell carcinoma. | No subsidy | 1200 | 600 |
Letrozole | Letrozole tablet (2.5 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Leuprorelin | Leuprorelin acetate injection (3.75 mg) | Lucrin | Treatment of breast cancer in pre- and perimenopausal women in whom hormone therapy is specified. | MAF | 200 | 600 |
Leuprorelin | Leuprorelin acetate injection (3.75 mg, 5 mg/ml, 7.5 mg, 11.25 mg, 22.5 mg, 30 mg, 45 mg) | Lucrin
Eligard | 1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse.
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer | MAF | 200 | 600 |
Liposomal doxorubicin | Doxorubicin hydrochloride (pegylated liposome) concentrate for infusion (20 mg/10 mL) | - | For cancer treatment. | SDL (Chemodox) | 1400 | 600 |
Liposomal irinotecan | Pegylated liposomal irinotecan concentrate for dispersion for infusion (43 mg/10 mL) | Onivyde | Liposomal irinotecan in combination with fluorouracil and leucovorin, for patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. | No subsidy | 200 | 600 |
Lomustine | Lomustine capsule (40 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Lorlatinib | Lorlatinib tablet (25 mg, 100 mg) | Lorviqua | Treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer whose disease has progressed after an ALK inhibitor other than crizotinib. | No subsidy | 2000 | 600 |
Lutetium oxodotreotide | Lutetium-177 (177-Lu) peptide | - | Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor-positive gastro-entero-pancreatic neuroendocrine tumours (NETs), including foregut, midgut, and hindgut NETs in adults. | No subsidy | 1200 | 600 |
Lutetium PSMA | Lutetium PSMA | - | Treatment of adults with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen. | No subsidy | 1400 | 600 |
Megestrol | Megestrol tablet (40 mg, 160 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Melphalan | Melphalan injection (50 mg) | Alkeran | For cancer treatment. | SDL | 400 | 600 |
Melphalan | Melphalan tablet (2 mg) | Alkeran | For cancer treatment. | SDL | 200 | 600 |
Mercaptopurine | Mercaptopurine tablet (50 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Meta-iodobenzylguanidine [I-131] | Meta-iodobenzylguanidine [I-131] injection for therapeutic use (185 to 740 MBq/mL) | - | Radiation therapy of tumours arising from cells originating embryologically from the neural crest, pheochromocytomas, neuroblastomas, carcinoids and medullary carcinomas of the thyroid gland. | No subsidy | 3000 | 600 |
Methotrexate | Methotrexate vial (50 mg/2 mL, 1g/10 mL) | - | For cancer treatment. | SDL | 400 | 600 |
Methotrexate | Methotrexate tablet (2.5 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Methylprednisolone | Methylprednisolone vial (62.5mg/mL) | - | For cancer treatment. | SDL | 200 | 600 |
Midostaurin | Midostaurin tablet (25 mg) | Rydapt | Treatment of FLT-3-mutation positive acute myeloid leukaemia (AML) in combination with standard intensive induction and consolidation chemotherapy. Standard induction chemotherapy must include cytarabine and an anthracycline.
Midostaurin is not recommended for maintenance therapy. | MAF | 2400 | 600 |
Mitomycin | Mitomycin injection (2 mg, 10 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Mitoxantrone | Mitoxantrone vial (20 mg/10 mL) | - | For cancer treatment. | SDL | 1000 | 600 |
Nab-paclitaxel | Paclitaxel - albumin bound nanoparticles injectable suspension (100 mg) | Abraxane | Monotherapy for breast cancer in adults who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. | MAF | 1000 | 600 |
Nab-paclitaxel | Paclitaxel - albumin bound nanoparticles injectable suspension (100 mg) | Abraxane | Nab-paclitaxel in combination with gemcitabine, for previously untreated metastatic adenocarcinoma of the pancreas. | MAF | 1000 | 600 |
Nab-paclitaxel | Paclitaxel - albumin bound nanoparticles injectable suspension (100 mg) | Abraxane | Nab-paclitaxel in combination with carboplatin, for previously untreated locally advanced or metastatic non-small cell lung cancer in patients who are not candidates for curative surgery or radiation therapy. | MAF | 1000 | 600 |
Nilotinib | Nilotinib capsule (50 mg, 150 mg, 200 mg) | Tasigna | Treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase. | MAF | 1200 | 600 |
Nilotinib | Nilotinib capsule (50 mg, 150 mg, 200 mg) | Tasigna | Treatment of adults with treatment-resistant or treatment-intolerant chronic myeloid leukaemia (CML) in chronic phase or accelerated phase; or children with treatment-resistant or treatment-intolerant CML in chronic phase. | MAF | 1200 | 600 |
Nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) | Opdivo | Treatment of patients with unresectable locally advanced or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma after 2 or more prior systemic therapies. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for gastric or GEJ cancer. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. | MAF | 1800 | 600 |
Nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) | Opdivo | Treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for MSI-H or dMMR CRC. The dose of nivolumab should not exceed 240mg every 2 weeks or 480mg every 4 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) | Opdivo | Nivolumab in combination with ipilimumab for treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for MSI-H or dMMR CRC. The doses of nivolumab and ipilimumab should not exceed: 3mg/kg nivolumab and 1mg/kg ipilimumab every 3 weeks for 4 doses, followed by nivolumab 240mg every 2 weeks or 480mg every 4 weeks as a single agent. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. Re-induction with ipilimumab is not allowed. | No subsidy | 1800 | 600 |
Nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) | Opdivo | Treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. | MAF | 1800 | 600 |
Nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) | Opdivo | Treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) after receiving platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for UC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) | Opdivo | Treatment of advanced unresectable hepatocellular carcinoma (HCC) in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for HCC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) | Opdivo | Nivolumab in combination with ipilimumab for treatment of advanced unresectable hepatocellular carcinoma (HCC) in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for HCC. The doses of nivolumab and ipilimumab should not exceed: 1mg/kg nivolumab and 3mg/kg ipilimumab every 3 weeks for 4 doses, followed by nivolumab 240mg every 2 weeks or 480mg every 4 weeks as a single agent. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. Re-induction with ipilimumab is not allowed. | No subsidy | 1800 | 600 |
Nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) | Opdivo | Nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy, for previously untreated metastatic or recurrent non-small cell lung cancer (NSCLC) in patients with no EGFR or ALK genomic tumour mutations. The doses of nivolumab and ipilimumab should not exceed: 360mg nivolumab every 3 weeks and 1mg/kg ipilimumab every 6 weeks. Treatment with nivolumab and ipilimumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) | Opdivo | For previously treated advanced renal cell carcinoma (RCC). Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for RCC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. | MAF | 1800 | 600 |
Nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) | Opdivo | Adjuvant treatment of completely resected malignant melanoma in patients with lymph node involvement. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Maximum duration of treatment: 12 months. | MAF | 1800 | 600 |
Nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) | Opdivo | Monotherapy for advanced unresectable or metastatic malignant melanoma. Patients must not have received prior treatment with a PD-1 inhibitor or ipilimumab for unresectable or metastatic melanoma. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. | MAF | 1800 | 600 |
Nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) | Opdivo | For untreated intermediate- or poor-risk advanced renal cell carcinoma, following induction treatment with nivolumab in combination with ipilimumab. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. | MAF | 1800 | 600 |
Nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) | Opdivo | Nivolumab in combination with ipilimumab for the treatment of advanced unresectable or metastatic malignant melanoma. Patients must not have received prior treatment with a PD-1 inhibitor or ipilimumab for unresectable or metastatic melanoma. The doses of nivolumab and ipilimumab should not exceed: 1mg/kg nivolumab and 3mg/kg ipilimumab every 3 weeks for 4 doses, followed by 3 mg/kg nivolumab every 2 weeks as a single agent. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. Re-induction with ipilimumab is not allowed. | No subsidy | 1800 | 600 |
Nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) | Opdivo | For patients with unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN) whose disease progressed within six months of starting platinum-based chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for RMSCCHN. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. | MAF | 1800 | 600 |
Nivolumab | Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) | Opdivo | Treatment of adults with relapsed or refractory classical Hodgkin lymphoma (cHL) after an autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for relapsed or refractory cHL. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if the person has an allogeneic stem cell transplant or the disease progresses.
| MAF | 1800 | 600 |
Obinutuzumab | Obinutuzumab concentrate for solution for infusion (1000 mg/40 mL) | Gazyva | Obinutuzumab in combination with chemotherapy, for previously untreated stage II bulky, III or IV follicular lymphoma. Patients achieving at least a partial remission may continue to receive maintenance treatment with obinutuzumab monotherapy. Maintenance treatment with obinutuzumab should be stopped after 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Obinutuzumab | Obinutuzumab concentrate for solution for infusion (1000 mg/40 mL) | Gazyva | Obinutuzumab in combination with bendamustine, for the treatment of follicular lymphoma that has not responded to or progressed within 6 months after treatment with rituximab or a rituximab-containing regimen. Patients must not have received obinutuzumab for follicular lymphoma. Maintenance treatment with obinutuzumab should be stopped at 2 years, or earlier if disease progresses. | MAF | 1800 | 600 |
Octreotide | Octreotide long-acting depot injection (20 mg, 30 mg) | Sandostatin LAR | For cancer treatment. | SDL | 600 | 600 |
Olaparib | Olaparib tablet (100 mg, 150 mg) | Lynparza | Maintenance treatment of patients with deleterious or suspected deleterious germline BRCA mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. | MAF | 1600 | 600 |
Olaparib | Olaparib tablet (100 mg, 150 mg) | Lynparza | Treatment of germline BRCA-mutated, HER2 negative, locally advanced or metastatic breast cancer in patients previously treated with chemotherapy. | MAF | 1600 | 600 |
Olaparib | Olaparib tablet (100 mg, 150 mg) | Lynparza | Treatment of adults with metastatic castration-resistant prostate cancer and homologous recombination repair gene BRCA1/2 and/or ATM-mutations (germline and/or somatic) who have progressed following a prior treatment with abiraterone or second generation anti-androgen. | MAF | 1600 | 600 |
Olaparib | Olaparib tablet (100 mg, 150 mg) | Lynparza | Maintenance monotherapy for adults with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
Treatment should be continued until disease progression or unacceptable toxicity or a maximum of 24 months. | MAF | 1600 | 600 |
Olaparib | Olaparib tablet (100 mg, 150 mg) | Lynparza | Olaparib in combination with bevacizumab as maintenance treatment of adults with advanced homologous recombination deficiency (HRD) positive high grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab.
Treatment with olaparib should be continued until disease progression or unacceptable toxicity or a maximum of 24 months. | MAF | 1600 | 600 |
Olaparib | Olaparib tablet (100 mg, 150 mg) | Lynparza | Maintenance monotherapy for adults with platinum-sensitive relapsed BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Patients must not have received prior treatment with a PARP inhibitor for ovarian cancer. Treatment should be continued until disease progression or unacceptable toxicity.
| MAF | 1600 | 600 |
Osimertinib | Osimertinib tablet (40 mg, 80 mg) | Tagrisso | For previously untreated locally advanced or metastatic EGFR mutation positive non-small cell lung cancer. | No subsidy | 600 | 600 |
Osimertinib | Osimertinib tablet (40 mg, 80 mg) | Tagrisso | Treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR TKI therapy. | MAF | 600 | 600 |
Osimertinib | Osimertinib tablet (40 mg, 80 mg) | Tagrisso | Adjuvant treatment after tumour resection in patients with stage IB to IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. Treatment should be continued until disease recurrence or unacceptable toxicity or a maximum of 3 years. | No subsidy | 600 | 600 |
Oxaliplatin | Oxaliplatin injection (50 mg/10 mL, 100 mg/50 mL, 200 mg/40 mL) | - | For cancer treatment. | SDL | 200 | 600 |
Paclitaxel | Paclitaxel vial (150 mg/25 mL, 300 mg/50 mL) | - | For cancer treatment. | SDL | 200 | 600 |
Palbociclib | Palbociclib capsule (75 mg, 100 mg, 125 mg) | Ibrance | Palbociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer. | MAF | 800 | 600 |
Palbociclib | Palbociclib capsule (75 mg, 100 mg, 125 mg) | Ibrance | Palbociclib in combination with fulvestrant for treating HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy. | MAF | 800 | 600 |
Panitumumab | Panitumumab concentrate for solution for infusion (100 mg/5 mL) | Vectibix | For cancer treatment. | SDL | 1000 | 600 |
Pazopanib | Pazopanib tablet (200 mg, 400 mg) | Votrient | For cancer treatment. | SDL | 1600 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Adjuvant treatment of completely resected malignant melanoma in patients with lymph node involvement. Maximum duration of treatment: 12 months. | MAF | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Treatment of advanced unresectable or metastatic malignant melanoma. Patients must not have received a PD-1 inhibitor or ipilimumab for unresectable or metastatic melanoma. Treatment with PD-1 inhibitor should be stopped at 2 years, or earlier if disease progresses. | MAF | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Treatment of metastatic Merkel cell carcinoma. | MAF | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Pembrolizumab in combination with axitinib for untreated advanced renal cell carcinoma. Treatment with PD-1/PD-L1 inhibitor should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Monotherapy for previously untreated unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN) with PD-L1 CPS≥1. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. | MAF | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Pembrolizumab in combination with platinum-based chemotherapy, for previously untreated unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN) with PD-L1 CPS≥1. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. | MAF | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Pembrolizumab in combination with lenvatinib for treating advanced endometrial carcinoma that is not microsatellite instability-high (non-MSI-H) or mismatch repair deficient (non-dMMR), who have disease progression following prior chemotherapy in the metastatic setting and are not candidates for curative surgery or radiation. | No subsidy | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | For previously untreated metastatic non-small cell lung cancer (NSCLC) in patients whose tumours express PD-L1 with a tumour proportion score ≥50%, with no EGFR or ALK genomic tumour aberrations.Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. | MAF | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Treatment of patients with metastatic non-small cell lung cancer (NSCLC), whose tumours express PD-L1 with a tumour proportion score ≥1% and had disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. | MAF | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Pembrolizumab in combination with carboplatin and nab- paclitaxel for previously untreated metastatic squamous non-small cell lung cancer (NSCLC). Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Pembrolizumab in combination with carboplatin and paclitaxel for previously untreated metastatic squamous non-small cell lung cancer (NSCLC). Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. | MAF | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Pembrolizumab in combination with pemetrexed and platinum chemotherapy, for previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC) in patients with no EGFR or ALK genomic tumour aberrations. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. | MAF | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Treatment of advanced unresectable hepatocellular carcinoma (HCC) in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for HCC. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prior treatment and who have no satisfactory alternative treatment options. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for a MSI-H or dMMR solid tumour. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Treatment of patients with locally advanced or metastatic urothelial carcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥10, and who are not eligible for cisplatin-containing chemotherapy. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. | No subsidy | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) after receiving platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for UC. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. | MAF | 1800 | 600 |
Pembrolizumab | Pembrolizumab solution for infusion (100 mg/4 mL) | Keytruda | Treatment of patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for relapsed or refractory cHL. Treatment with pembrolizumab should be stopped at 2 years, or earlier if the person has a stem cell transplant or the disease progresses. | MAF | 1800 | 600 |
Pemetrexed | Pemetrexed injection (100 mg, 500 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Pertuzumab | Pertuzumab concentrate for solution for infusion (420 mg/14 mL) | Perjeta | Pertuzumab in combination with trastuzumab and chemotherapy for neoadjuvant treatment of HER2 positive locally advanced, inflammatory or early stage (tumour >2 cm in diameter or node positive) breast cancer for 4 to 6 cycles. Following surgery, patients may continue with trastuzumab with or without pertuzumab for a total of 1 year of anti-HER2 treatment. | No subsidy | 2400 | 600 |
Pertuzumab | Pertuzumab concentrate for solution for infusion (420 mg/14 mL) | Perjeta | Pertuzumab in combination with trastuzumab and chemotherapy for adjuvant treatment of high-risk (with positive nodes) HER2 positive early breast cancer for a maximum duration of 1 year. | No subsidy | 2400 | 600 |
Pertuzumab | Pertuzumab concentrate for solution for infusion (420 mg/14 mL) | Perjeta | Pertuzumab in combination with trastuzumab and a taxane for HER2 positive metastatic or locally recurrent breast cancer, in patients without prior treatment for metastatic disease. Treatment with pertuzumab should be stopped if disease progresses. | No subsidy | 2400 | 600 |
Pertuzumab + trastuzumab | Pertuzumab / trastuzumab solution for subcutaneous injection (1200 mg/600 mg, 600 mg/600 mg)
| Phesgo | In combination with chemotherapy for neoadjuvant treatment of HER2-positive locally advanced, inflammatory or early stage (tumour >2 cm in diameter or node positive) breast cancer for 4 to 6 cycles. Following surgery, patients may continue with trastuzumab with or without pertuzumab for a total of 1 year of anti-HER2 treatment.
| No subsidy | 2400 | 600 |
Pertuzumab + trastuzumab | Pertuzumab / trastuzumab solution for subcutaneous injection (1200 mg/600 mg, 600 mg/600 mg) | Phesgo | In combination with chemotherapy for adjuvant treatment of high-risk (with positive nodes) HER2-positive early breast cancer for a maximum duration of 1 year.
| No subsidy | 2400 | 600 |
Pertuzumab + trastuzumab | Pertuzumab / trastuzumab solution for subcutaneous injection (1200 mg/600 mg, 600 mg/600 mg)
| Phesgo | In combination with a taxane for treating HER2-positive metastatic or locally recurrent breast cancer, in patients without prior treatment for metastatic disease. Treatment with pertuzumab should be stopped if disease progresses.
| No subsidy | 2400 | 600 |
Pomalidomide | Pomalidomide capsule (1 mg, 2 mg, 3 mg, 4 mg) | Pomalyst | Pomalidomide in combination with bortezomib or cyclophosphamide, plus dexamethasone, for patients with multiple myeloma who have received at least one prior therapy. | MAF | 2000 | 600 |
Pomalidomide | Pomalidomide capsule (1 mg, 2 mg, 3 mg, 4 mg) | Pomalyst | Pomalidomide in combination with dexamethasone for patients with multiple myeloma who have received at least two prior therapies, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy. | MAF | 2000 | 600 |
Ponatinib | Ponatinib tablet (15 mg) | Iclusig | Treatment of chronic, accelerated, or blast phase chronic myeloid leukaemia (CML) in adults:
• whose disease is resistant to imatinib or dasatinib or nilotinib, and who have the T315I mutation OR
• whose disease is resistant to both nilotinib and dasatinib OR
• whose disease is resistant to nilotinib or dasatinib and who are intolerant of/contraindicated to the other drug. | MAF | 1200 | 600 |
Ponatinib | Ponatinib tablet (15 mg) | Iclusig | Treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukaemia who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. | MAF | 1200 | 600 |
Prednisolone | Prednisolone tablet (1 mg, 5 mg, 20 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Procarbazine | Procarbazine capsule (50 mg) | - | For cancer treatment. | SDL | 800 | 600 |
Radium-223 | Radium-223 solution for injection (1100 kBq/mL) | Xofigo | Treatment of patients with castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease. | No subsidy | 1400 | 600 |
Ramucirumab | Ramucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL) | Cyramza | Treatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have serum alpha-fetoprotein (AFP) of ≥400 ng/ml, and have adequate liver function as assessed by the Child-Pugh scoring system. | No subsidy | 1800 | 600 |
Ramucirumab | Ramucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL) | Cyramza | Ramucirumab as monotherapy for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. | No subsidy | 1800 | 600 |
Ramucirumab | Ramucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL) | Cyramza | Ramucirumab in combination with paclitaxel for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. | No subsidy | 1800 | 600 |
Ramucirumab | Ramucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL) | Cyramza | Ramucirumab in combination with FOLFIRI for treating metastatic colorectal cancer that has progressed on first-line systemic therapy. | No subsidy | 1800 | 600 |
Regorafenib | Regorafenib tablet (40 mg) | Stivarga | Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumour (GIST) who have been previously treated with imatinib mesylate. | MAF | 1800 | 600 |
Regorafenib | Regorafenib tablet (40 mg) | Stivarga | Treatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. | MAF | 1800 | 600 |
Regorafenib | Regorafenib tablet (40 mg) | Stivarga | Treatment of metastatic colorectal cancer that has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy. | MAF | 1800 | 600 |
Ribociclib | Ribociclib tablet (200 mg) | Kisqali | Ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer. | MAF | 800 | 600 |
Ribociclib | Ribociclib tablet (200 mg) | Kisqali | Ribociclib in combination with fulvestrant for HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy. | MAF | 800 | 600 |
Rituximab | Rituximab biosimilar concentrate for infusion (100 mg/10 mL, 500 mg/50 mL) | Truxima | For cancer treatment. | SDL (Truxima) | 1000 | 600 |
Rituximab | Rituximab concentrate for infusion (100 mg/10 mL, 500 mg/50 mL) | Mabthera
Rixathon | For cancer treatment. | No subsidy | 1000 | 600 |
Rituximab | Rituximab solution for subcutaneous injection (1400 mg/11.7 mL) | Mabthera | Rituximab (subcutaneous) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), for the treatment of CD20+ diffuse large B-cell non-Hodgkin lymphoma. | No subsidy | 1000 | 600 |
Rituximab | Rituximab solution for subcutaneous injection (1400 mg/11.7 mL) | Mabthera | Rituximab (subcutaneous) in combination with cyclophosphamide, vincristine, prednisone (CVP), for the treatment of previously untreated patients with stage III-IV follicular lymphoma. | No subsidy | 1000 | 600 |
Rituximab | Rituximab solution for subcutaneous injection (1400 mg/11.7 mL) | Mabthera | Rituximab (subcutaneous) for maintenance treatment of patients with follicular lymphoma who have responded to induction therapy. | No subsidy | 1000 | 600 |
Romidepsin | Romidepsin powder for solution for infusion (10 mg) | - | Treatment of peripheral T-cell lymphoma in adults who have received at least one prior therapy. | No subsidy | 1800 | 600 |
Ruxolitinib | Ruxolitinib tablet (5 mg, 15 mg, 20 mg) | Jakavi |
Treatment of patients with intermediate-2 or high-risk myelofibrosis with disease-related splenomegaly or symptoms. | MAF | 2000 | 600 |
Siltuximab | Siltuximab powder for infusion (100 mg) | Sylvant | Treatment of adults with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. | No subsidy | 3000 | 600 |
Sodium iodide [I-131] | Sodium iodide [I-131] capsule (37 to 6000 MBq) | - | For thyroid residue ablation after surgery of differentiated thyroid cancer, and treatment of iodine-accumulating metastases. | No subsidy | 1600 | 600 |
Sorafenib | Sorafenib tablet (200 mg) | Nexavar | For cancer treatment. | SDL | 1200 | 600 |
Sunitinib | Sunitinib capsule (12.5 mg, 25 mg, 37.5 mg, 50 mg) | Sutent | Treatment of patients with unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) who have had an inadequate response to imatinib mesylate treatment due to resistance or intolerance. | No subsidy | 1600 | 600 |
Sunitinib | Sunitinib capsule (12.5 mg, 25 mg, 37.5 mg, 50 mg) | Sutent | Treatment of advanced renal cell carcinoma. | No subsidy | 1600 | 600 |
Sunitinib | Sunitinib capsule (12.5 mg, 25 mg, 37.5 mg, 50 mg) | Sutent | Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease progression. | No subsidy | 1600 | 600 |
Talazoparib | Talazoparib capsule (0.25 mg, 1 mg) | Talzenna | Treatment of germline BRCA-mutated, HER2 negative, locally advanced or metastatic breast cancer in patients previously treated with chemotherapy. | No subsidy | 1600 | 600 |
Tamoxifen | Tamoxifen tablet (20 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Tegafur + gimeracil+ oteracil | Tegafur + gimeracil + oteracil potassium capsule (20 mg/5.8 mg/19.6 mg, 25 mg/7.25 mg/24.5 mg) | TS-ONE | Treatment of locally advanced or metastatic adenocarcinoma of the pancreas. | No subsidy | 200 | 600 |
Tegafur + gimeracil+ oteracil | Tegafur + gimeracil + oteracil potassium capsule (20 mg/5.8 mg/19.6 mg, 25 mg/7.25 mg/24.5 mg) | TS-ONE | Post-operative adjuvant treatment of locally advanced (stage II (excluding T1), IIIA or IIIB) gastric cancer. | No subsidy | 200 | 600 |
Temozolomide | Temozolomide capsule (20 mg, 100 mg) | - | For cancer treatment. | SDL | 800 | 600 |
Thalidomide | Thalidomide capsule (50 mg) | - | For cancer treatment. | SDL | 400 | 600 |
Tioguanine | Tioguanine tablet (40 mg) | - | For cancer treatment. | SDL | 1600 | 600 |
Trabectedin | Trabectedin powder for injection (1 mg) | Yondelis | Treatment of patients with advanced or metastatic soft tissue sarcoma, after failure of anthracyclines and ifosfamide (unless unsuitable). | No subsidy | 1200 | 600 |
Trastuzumab | Trastuzumab biosimilar powder for IV infusion (440 mg) | Ogivri Herzuma | For cancer treatment. | SDL (Ogivri, Herzuma) | 600 | 600 |
Trastuzumab | Trastuzumab powder for IV infusion (440 mg) | Herceptin Kanjinti
Trazimera | For cancer treatment. | No subsidy | 600 | 600 |
Trastuzumab | Trastuzumab solution for SC injection (600 mg/5 mL) | Herceptin | For cancer treatment. | No subsidy | 600 | 600 |
Trastuzumab emtansine | Trastuzumab emtansine powder for concentrate for infusion solution (100 mg, 160 mg) | Kadcyla | Adjuvant treatment of HER2 positive early breast cancer in patients with residual invasive disease, after neoadjuvant treatment with trastuzumab and a taxane. Maximum 14 cycles. | No subsidy | 2400 | 600 |
Trastuzumab emtansine | Trastuzumab emtansine powder for concentrate for infusion solution (100 mg, 160 mg) | Kadcyla | Treatment of HER2 positive, locally advanced, unresectable, or metastatic breast cancer in patients who have received prior treatment with trastuzumab and a taxane. | No subsidy | 2400 | 600 |
Tretinoin | Tretinoin capsule (10 mg) | Vesanoid | For cancer treatment. | SDL | 800 | 600 |
Trifluridine + tipiracil | Trifluridine + tipiracil tablet (15 mg/6.14 mg, 20 mg/8.19 mg) | Lonsurf | Treatment of metastatic colorectal cancer that has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy. | No subsidy | 1800 | 600 |
Trifluridine + tipiracil | Trifluridine + tipiracil tablet (15 mg/6.14 mg, 20 mg/8.19 mg) | Lonsurf | Treatment of patients with unresectable locally advanced or recurrent gastric or gastroesophageal junction adenocarcinoma after 2 or more prior systemic therapies. | No subsidy | 1800 | 600 |
Triptorelin | Triptorelin injection (3.75 mg, 11.25 mg, 22.5 mg) | - | Treatment of locally advanced or metastatic, hormone-dependent prostate cancer. | No subsidy | 200 | 600 |
Venetoclax | Venetoclax tablet (10 mg, 50 mg, 100 mg) | Venclexta | Monotherapy after completion of 6 cycles of obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia (CLL) who are unsuitable for fludarabine-based therapy. | MAF | 3000 | 600 |
Venetoclax | Venetoclax tablet (10 mg, 50 mg, 100 mg) | Venclexta | Venetoclax in combination with rituximab biosimilar for patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. Maximum treatment duration of rituximab is 6 cycles and venetoclax is 24 months. | MAF | 3000 | 600 |
Venetoclax | Venetoclax tablet (10 mg, 50 mg, 100 mg) | Venclexta | Treatment of newly diagnosed acute myeloid leukaemia (AML) in combination with a hypomethylating agent or low-dose cytarabine in patients who are ineligible for intensive chemotherapy. | No subsidy | 3000 | 600 |
Venetoclax plus obinutuzumab | Venetoclax tablet (10 mg, 50 mg, 100 mg) Obinutuzumab concentrate for solution for infusion (1000 mg/40 mL)
| Venclexta
Gazyva | Venetoclax in combination with obinutuzumab for patients with previously untreated chronic lymphocytic leukemia (CLL) who are unsuitable for fludarabine-based therapy. Maximum treatment duration of obinutuzumab is 6 cycles and venetoclax is 12 months. | MAF | 5400 | 600 |
Vinblastine sulfate | Vinblastine sulfate vial (10 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Vincristine sulfate | Vincristine sulfate vial (1 mg) | - | For cancer treatment. | SDL | 200 | 600 |
Vinflunine | Vinflunine concentrate for solution for infusion (50 mg/2 mL, 100 mg/4 mL, 250 mg/10 mL) | Javlor | Treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy. | No subsidy | 1800 | 600 |
Vinorelbine | Vinorelbine capsule (20 mg, 30 mg) | - | (Undergoing Evaluation) | (Undergoing Evaluation) | (Undergoing Evaluation) | (Undergoing Evaluation) |
Vinorelbine | Vinorelbine injection (50 mg/5 mL) | - | For cancer treatment. | SDL | 400 | 600 |